Date: 2016-11-29
Type of information: Licensing agreement
Compound: three specific NAV vector sequences covered by NAV Technology Platform
Company: RegenXBio (USA - MD) Voyager Therapeutics (USA - MA)
Therapeutic area: Neurological diseases
Type agreement: licensing
Action mechanism: gene therapy
Disease: neurological diseases
Details: • On November 29, 2016, Regenxbio and Voyager Therapeutics, announced that Voyager has exercised commercial options for the use of Regenxbio’s NAV vectors for the development and commercialization of gene therapies for specific neurological diseases. Upon exercise of the options, Regenxbio has granted Voyager a non-exclusive worldwide commercial license, with rights to sublicense, to three specific NAV vector sequences covered by Regenxbio’s NAV Technology Platform, each for the treatment of a specific neurological disease. Voyager Therapeutics’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Friedreich’s ataxia, Huntington’s disease, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Financial terms: In return for these rights, Regenxbio will receive undisclosed upfront payments, ongoing fees, milestone payments and royalties on net sales of products incorporating the licensed intellectual property.
Latest news:
